Intraseasonal Short-time Up-dosing With Alutard SQ Grasses

A Randomised, Parallel-group, Double-blind, Placebo-controlled, Multicentre Phase III Trial Assessing the Pharmacodynamic Efficacy and Safety of an Intra-seasonal Short-time Updosing Schedule for Alutard SQ

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00807547

Enrollment

149

Registered

2008-12-12

Start date

2008-04-30

Completion date

2009-01-31

Last updated

2015-12-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergy

Brief summary

Test of pharmacodynamic efficacy and tolerability of a short-time intra-seasonal updosing

Interventions

BIOLOGICALAllergy vaccination (Alutard SQ)

Alutard SQ grasses and rye, 8 subcutaneous injections, updosing to 10.000 SQ-U, duration of treatment 50 days

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* history of grass pollen induced allergic rhinoconjunctivitis * positive skin prick test

Exclusion criteria

* uncontrolled severe bronchial asthma * previous treatment with immunotherapy within the previous 5 years * contraindication for specific immunotherapy

Design outcomes

Primary

Measure	Time frame
Changes from baseline in Immuno globuline E (IgE)-blocking factor	9 weeks

Secondary

Measure	Time frame
Tolerability	9 weeks

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 25, 2026